Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
Evaluate Pharma
Evaluate Omnium
Evaluate Epi
Japan Drug Forecasts
Europe Drug Forecasts
Pharma Consulting & Analytics
Pharma Consulting & Analytics
Data Feeds and APIs
Evaluate Vantage
News
Analysis
Policy & Pricing
Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
Evaluate for Biotech
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Contact Us
Sign Up for Evaluate Vantage
Talent
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
OncoMed Pharmaceuticals
September 21, 2017
Taiho shows Arcus trying to repeat the Flexus trick
April 21, 2017
Snippet roundup: Tesaro's Parp pricing stumble and Asco sneak peek
April 11, 2017
Double trouble sinks Oncomed as investors look to earlier assets
January 24, 2017
Asco-GI – Pancreatic cancer field awaits sparse data
September 29, 2016
Esmo preview – Novel checkpoints add to the Parp showdown
August 26, 2016
Esmo preview – A Merck versus Bristol showdown
April 29, 2016
AbbVie caps week of cancer deals with huge Stemcentrx takeout
February 05, 2016
Pancreatic cancer 2016: this time it’s (getting) personal
February 03, 2016
No safe haven as January crash wipes $644bn off biopharma
January 26, 2016
OncoMed digs itself out from under Alpine avalanche
September 17, 2014
Esmo preview – Immuno-oncology and beyond
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
September 03, 2021
Biopharma and Medtech Half-Year Review 2021
May 27, 2021
Evaluate Vantage Biopharma and Venture Capital: A Deep Dive
Editor's Picks
September 13, 2021
Esmo 2021 – Mirati bids to be belle of the ball
September 03, 2021
World Lung 2021 preview – China challenges and tremelimumab rises
September 07, 2021
Roche U-turns and Adaptimmune wins
September 02, 2021
Tecentriq pullout dominates the latest PD-(L)1 moves
September 06, 2021
Another gene therapy safety scare hits
